The identification of empirically derived cancer patient subgroups using psychosocial variables.

Objective: To determine if there are subgroups of cancer patients who differ on coping, psychological, and quality of life (QOL) measures, and to determine if these subgroups have a different course of distress and health following a cancer diagnosis.

Methods: Three hundred fifty-one individuals presenting to a multidisciplinary melanoma clinic completed a baseline questionnaire packet containing the Brief Symptom Inventory (BSI), the Medical Outcomes Survey Short-Form 36 (SF-36), Ways of Coping (WOC), State-Trait Anxiety Inventory (STAI), an informed consent form, and a demographic questionnaire. Participants subsequently completed measures at 2, 5, and 9 months after completion of their baseline assessment.

Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy.

Prostate cancer continues to occur in over 230,000 men each year. Although the majority of these will be diagnosed in the early stages, there remains a proportion who will either be diagnosed in late stage disease or develop progressive disease. In patients with advanced disease, research has recently focused on using chemotherapy for symptom management and palliation.

Psychological and fitness changes associated with exercise participation among women with breast cancer.

Exercise participation has been shown to improve cardiovascular fitness and reduce psychological distress among women receiving chemotherapy and/or radiation. The purpose of this pilot study was to examine the changes in distress and body image, and fitness following exercise participation among 24 women who had been diagnosed with breast cancer within the previous 3 years. The women were randomly assigned to participate in a 12-week supervised aerobic exercise program in a hospital setting or a wait-list control group.

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment.